Page 17 - FLIPBOOK
P. 17
STAMPEDE
• Recruits men from 4 groups starting long-term ADT:
1. High-risk localised (T3/4, PSA >40 or Gleason 8-10)
2. Node-positive (N+) prostate cancer
3. Newly-diagnosed metastatic (M1)
4. high-risk recurrence post surgery or RT
• Radical radiotherapy in standard care:
– N+M0 patients; optional
– N0M0 patients; optional Oct 2005 – Nov 2011, mandatory from Nov-2011
www.stampedetrial.org
